{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T19:31:42Z","timestamp":1793043102764,"version":"4.5.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T00:00:00Z","timestamp":1758240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T00:00:00Z","timestamp":1758240000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009857","name":"Regeneron Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009857","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Clin Dermatol"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1007\/s40257-025-00962-8","type":"journal-article","created":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T08:45:16Z","timestamp":1758271516000},"page":"1031-1043","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Systemic Treatments in Moderate-to-Severe Atopic Dermatitis in Pediatric Patients up to 12 Years of Age: Real-World Treatment Outcomes from the PEDISTAD Registry"],"prefix":"10.1007","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6187-6549","authenticated-orcid":false,"given":"Amy S.","family":"Paller","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2079-9166","authenticated-orcid":false,"given":"Danielle","family":"Marcoux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9191-3611","authenticated-orcid":false,"given":"Michele","family":"Ramien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1086-8439","authenticated-orcid":false,"given":"Eulalia","family":"Baselga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4578-8781","authenticated-orcid":false,"given":"Vania Oliveira","family":"Carvalho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4179-2126","authenticated-orcid":false,"given":"Ledit R. F.","family":"Ardusso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9004-5111","authenticated-orcid":false,"given":"Marlies","family":"de Graaf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1018-4475","authenticated-orcid":false,"given":"Suzanne","family":"Pasmans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9132-9001","authenticated-orcid":false,"given":"Mirna","family":"Toledo-Bahena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cory","family":"Rubin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joel C.","family":"Joyce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6739-4508","authenticated-orcid":false,"given":"Lara Wine","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajan","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bryan","family":"Adams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7712-6862","authenticated-orcid":false,"given":"Marius","family":"Ardeleanu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annie","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,19]]},"reference":[{"issue":"1","key":"962_CR1","doi-asserted-by":"publisher","DOI":"10.4081\/dr.2012.e1","volume":"4","author":"G Ricci","year":"2011","unstructured":"Ricci G, Bellini F, Dondi A, Patrizi A, Pession A. Atopic dermatitis in adolescence. Dermatol Reports. 2011;4(1): e1. https:\/\/doi.org\/10.4081\/dr.2012.e1.","journal-title":"Dermatol Reports."},{"issue":"2","key":"962_CR2","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.aller.2012.03.001","volume":"41","author":"J Mallol","year":"2013","unstructured":"Mallol J, Crane J, von Mutius E, et al. The International Study of Asthma and Allergies in Childhood (ISAAC) phase three: a global synthesis. Allergol Immunopathol (Madr). 2013;41(2):73\u201385. https:\/\/doi.org\/10.1016\/j.aller.2012.03.001.","journal-title":"Allergol Immunopathol (Madr)"},{"issue":"4","key":"962_CR3","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.anai.2020.12.020","volume":"126","author":"JI Silverberg","year":"2021","unstructured":"Silverberg JI, Barbarot S, Gadkari A, et al. Atopic dermatitis in the pediatric population: a cross-sectional, international epidemiologic study. Ann Allergy Asthma Immunol. 2021;126(4):417-28.e2. https:\/\/doi.org\/10.1016\/j.anai.2020.12.020.","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"5","key":"962_CR4","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1080\/1744666X.2017.1298443","volume":"13","author":"NA Gandhi","year":"2017","unstructured":"Gandhi NA, Pirozzi G, Graham NMH. Commonality of the IL-4\/IL-13 pathway in atopic diseases. Expert Rev Clin Immunol. 2017;13(5):425\u201337. https:\/\/doi.org\/10.1080\/1744666X.2017.1298443.","journal-title":"Expert Rev Clin Immunol"},{"issue":"5","key":"962_CR5","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1016\/j.jaci.2013.08.031","volume":"132","author":"JI Silverberg","year":"2013","unstructured":"Silverberg JI, Hanifin JM. Adult eczema prevalence and associations with asthma and other health and demographic factors: a US population-based study. J Allergy Clin Immunol. 2013;132(5):1132\u20138. https:\/\/doi.org\/10.1016\/j.jaci.2013.08.031.","journal-title":"J Allergy Clin Immunol"},{"key":"962_CR6","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.anai.2023.11.009","volume":"132","author":"DK Chu","year":"2024","unstructured":"Chu DK, Schneider L, Asiniwasis RN, et al. Atopic dermatitis (eczema) guidelines: 2023 American Academy of Allergy, Asthma and Immunology\/American College of Allergy, Asthma and Immunology Joint Task Force on Practice Parameters GRADE- and Institute of Medicine-based recommendations. Ann Allergy Asthma Immunol. 2024;132:274\u2013312. https:\/\/doi.org\/10.1016\/j.anai.2023.11.009.","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"14","key":"962_CR7","doi-asserted-by":"publisher","first-page":"5147","DOI":"10.1073\/pnas.1323896111","volume":"111","author":"LE Macdonald","year":"2014","unstructured":"Macdonald LE, Karow M, Stevens S, et al. Precise and in situ genetic humanization of 6 Mb of mouse immunoglobulin genes. PNAS USA. 2014;111(14):5147\u201352. https:\/\/doi.org\/10.1073\/pnas.1323896111.","journal-title":"PNAS USA"},{"issue":"14","key":"962_CR8","doi-asserted-by":"publisher","first-page":"5153","DOI":"10.1073\/pnas.1324022111","volume":"111","author":"AJ Murphy","year":"2014","unstructured":"Murphy AJ, Macdonald LE, Stevens S, et al. Mice with megabase humanization of their immunoglobulin genes generate antibodies as efficiently as normal mice. PNAS USA. 2014;111(14):5153\u20138. https:\/\/doi.org\/10.1073\/pnas.1324022111.","journal-title":"PNAS USA"},{"issue":"1","key":"962_CR9","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1038\/nrd4624","volume":"15","author":"NA Gandhi","year":"2016","unstructured":"Gandhi NA, Bennett BL, Graham NMH, Pirozzi G, Stahl N, Yancopoulos GD. Targeting key proximal drivers of type 2 inflammation in disease. Nat Rev Drug Discov. 2016;15(1):35\u201350. https:\/\/doi.org\/10.1038\/nrd4624.","journal-title":"Nat Rev Drug Discov"},{"issue":"5","key":"962_CR10","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1111\/all.14151","volume":"75","author":"A Le Floc'h","year":"2020","unstructured":"Le Floc\u2019h A, Allinne J, Nagashima K, et al. Dual blockade of IL-4 and IL-13 with dupilumab, an IL-4R\u03b1 antibody, is required to broadly inhibit type 2 inflammation. Allergy. 2020;75(5):1188\u2013204. https:\/\/doi.org\/10.1111\/all.14151.","journal-title":"Allergy"},{"issue":"10356","key":"962_CR11","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1016\/S0140-6736(22)01539-2","volume":"400","author":"AS Paller","year":"2022","unstructured":"Paller AS, Simpson EL, Siegfried EC, et al. Dupilumab in children aged 6 months to younger than 6 years with uncontrolled atopic dermatitis: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2022;400(10356):908\u201319. https:\/\/doi.org\/10.1016\/S0140-6736(22)01539-2.","journal-title":"Lancet"},{"issue":"5","key":"962_CR12","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1016\/j.jaad.2020.06.054","volume":"83","author":"AS Paller","year":"2020","unstructured":"Paller AS, Siegfried EC, Tha\u00e7i D, et al. Efficacy and safety of dupilumab with concomitant topical corticosteroids in children 6 to 11 years old with severe atopic dermatitis: a randomized, double-blinded, placebo-controlled phase 3 trial. J Am Acad Dermatol. 2020;83(5):1282\u201393. https:\/\/doi.org\/10.1016\/j.jaad.2020.06.054. (Erratum in J\u00a0Am Acad Dermatol. 2021;84(1):230. 10.1016\/j.jaad.2020.10.013).","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"962_CR13","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2019-033507","volume":"10","author":"AS Paller","year":"2020","unstructured":"Paller AS, Guttman-Yassky E, Irvine AD, et al. Protocol for a prospective, observational, longitudinal study in paediatric patients with moderate-to-severe atopic dermatitis (PEDISTAD): study objectives, design and methodology. BMJ Open. 2020;10(3): e033507. https:\/\/doi.org\/10.1136\/bmjopen-2019-033507.","journal-title":"BMJ Open"},{"issue":"5","key":"962_CR14","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1016\/j.jaad.2022.01.018","volume":"87","author":"AS Paller","year":"2022","unstructured":"Paller AS, Guttman-Yassky E, Schuttelaar MLA, et al. Disease characteristics, comorbidities, treatment patterns and quality of life impact in children <12 years old with atopic dermatitis: interim results from the PEDISTAD Real-World Registry. J Am Acad Dermatol. 2022;87(5):1104\u20138. https:\/\/doi.org\/10.1016\/j.jaad.2022.01.018.","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"962_CR15","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1111\/bjd.15641","volume":"177","author":"R Chopra","year":"2017","unstructured":"Chopra R, Vakharia PP, Sacotte R, et al. Severity strata for Eczema Area and Severity Index (EASI), modified EASI, Scoring Atopic Dermatitis (SCORAD), objective SCORAD, Atopic Dermatitis Severity Index and body surface area in adolescents and adults with atopic dermatitis. Br J Dermatol. 2017;177(5):1316\u201321. https:\/\/doi.org\/10.1111\/bjd.15641.","journal-title":"Br J Dermatol"},{"issue":"1_suppl","key":"962_CR16","doi-asserted-by":"publisher","first-page":"10S","DOI":"10.1177\/1203475418803628","volume":"22","author":"MJ Gooderham","year":"2018","unstructured":"Gooderham MJ, Bissonnette R, Grewal P, Lansang P, Papp KA, Hong C-H. Approach to the assessment and management of adult patients with atopic dermatitis: a consensus document. Section II: tools for assessing the severity of atopic dermatitis. J Cutan Med Surg. 2018;22(1_suppl):10S-16S. https:\/\/doi.org\/10.1177\/1203475418803628.","journal-title":"J Cutan Med Surg"},{"issue":"3","key":"962_CR17","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1097\/DER.0000000000000895","volume":"33","author":"JM Hanifin","year":"2022","unstructured":"Hanifin JM, Baghoomian W, Grinich E, Leshem YA, Jacobson M, Simpson EL. The Eczema Area and Severity Index\u2014a practical guide. Dermatitis. 2022;33(3):187\u201392. https:\/\/doi.org\/10.1097\/DER.0000000000000895.","journal-title":"Dermatitis"},{"issue":"12","key":"962_CR18","doi-asserted-by":"publisher","first-page":"2839","DOI":"10.1007\/s13555-022-00804-z","volume":"12","author":"AS Paller","year":"2022","unstructured":"Paller AS, Yosipovitch G, Weidinger S, et al. Development, psychometric validation and responder definition of worst itch scale in children with severe atopic dermatitis. Dermatol Ther (Heidelb). 2022;12(12):2839\u201350. https:\/\/doi.org\/10.1007\/s13555-022-00804-z.","journal-title":"Dermatol Ther (Heidelb)."},{"issue":"2","key":"962_CR19","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1016\/j.jaad.2023.08.104","volume":"90","author":"AS Paller","year":"2024","unstructured":"Paller AS, Siegfried E, Marron SE, et al. Development and validation of a caregiver-reported numeric rating scale for measuring worst scratch\/itch in patients aged 6 months to younger than 6 years with atopic dermatitis. J Am Acad Dermatol. 2024;90(2):382\u20135. https:\/\/doi.org\/10.1016\/j.jaad.2023.08.104.","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"962_CR20","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1111\/bjd.12590","volume":"169","author":"CR Charman","year":"2013","unstructured":"Charman CR, Venn AJ, Ravenscroft JC, Williams HC. Translating Patient-Oriented Eczema Measure (POEM) scores into clinical practice by suggesting severity strata derived using anchor-based methods. Br J Dermatol. 2013;169(6):1326\u201332. https:\/\/doi.org\/10.1111\/bjd.12590.","journal-title":"Br J Dermatol"},{"issue":"4","key":"962_CR21","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1007\/s13555-019-00333-2","volume":"9","author":"EL Simpson","year":"2019","unstructured":"Simpson EL, de Bruin-Weller M, Eckert L, et al. Responder threshold for Patient-Oriented Eczema Measure (POEM) and Children\u2019s Dermatology Life Quality Index (CDLQI) in adolescents with atopic dermatitis. Dermatol Ther (Heidelb). 2019;9(4):799\u2013805. https:\/\/doi.org\/10.1007\/s13555-019-00333-2.","journal-title":"Dermatol Ther (Heidelb)."},{"issue":"4","key":"962_CR22","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1007\/s13555-021-00543-7","volume":"11","author":"EL Simpson","year":"2021","unstructured":"Simpson EL, de Bruin-Weller M, Bansal A, et al. Definition of clinically meaningful within-patient changes in POEM and CDLQI in children 6 to 11 years of age with severe atopic dermatitis. Dermatol Ther (Heidelb). 2021;11(4):1415\u201322. https:\/\/doi.org\/10.1007\/s13555-021-00543-7.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"1","key":"962_CR23","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1046\/j.1365-2133.1998.02034.x","volume":"138","author":"V Lawson","year":"1998","unstructured":"Lawson V, Lewis-Jones MS, Finlay AY, Reid P, Owens RG. The family impact of childhood atopic dermatitis: the Dermatitis Family Impact Questionnaire. Br J Dermatol. 1998;138(1):107\u201313. https:\/\/doi.org\/10.1046\/j.1365-2133.1998.02034.x.","journal-title":"Br J Dermatol"},{"issue":"5","key":"962_CR24","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1111\/bjd.13662","volume":"172","author":"YA Leshem","year":"2015","unstructured":"Leshem YA, Hajar T, Hanifin JM, Simpson EL. What the Eczema Area and Severity Index score tells us about the severity of atopic dermatitis: an interpretability study. Br J Dermatol. 2015;172(5):1353\u20137. https:\/\/doi.org\/10.1111\/bjd.13662.","journal-title":"Br J Dermatol"},{"key":"962_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2024.09.046","author":"AS Paller","year":"2024","unstructured":"Paller AS, de Bruin-Weller M, Marcoux D, et al. Real-world treatment outcomes of systemic treatments for moderate-to-severe atopic dermatitis in children aged less than 12 years: 2-year results from PEDIatric STudy in Atopic Dermatitis. J Am Acad Dermatol. 2024. https:\/\/doi.org\/10.1016\/j.jaad.2024.09.046. (Online ahead of print).","journal-title":"J Am Acad Dermatol"},{"issue":"10","key":"962_CR26","doi-asserted-by":"publisher","first-page":"851","DOI":"10.2340\/00015555-3219","volume":"99","author":"LFM Ari\u00ebns","year":"2019","unstructured":"Ari\u00ebns LFM, Gadkari A, van Os-Medendorp H, et al. Dupilumab versus cyclosporine for the treatment of moderate-to-severe atopic dermatitis in adults: indirect comparison using the Eczema Area and Severity Index. Acta Derm Venereol. 2019;99(10):851\u20137. https:\/\/doi.org\/10.2340\/00015555-3219.","journal-title":"Acta Derm Venereol"},{"key":"962_CR27","doi-asserted-by":"publisher","DOI":"10.1093\/bjd\/ljae287","author":"H Alexander","year":"2024","unstructured":"Alexander H, Malek R, Prieto-Merino D, et al. A prospective observational cohort study comparing the treatment effectiveness and safety of ciclosporin, dupilumab and methotrexate in adult and paediatric patients with atopic dermatitis: results from the UK-Irish A-STAR register. Br J Dermatol. 2024. https:\/\/doi.org\/10.1093\/bjd\/ljae287. (Online ahead of print).","journal-title":"Br J Dermatol"},{"key":"962_CR28","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1001\/jamadermatol.2020.0796","volume":"156","author":"AM Drucker","year":"2020","unstructured":"Drucker AM, Ellis AG, Bohdanowicz M, et al. Systemic immunomodulatory treatments for patients with atopic dermatitis: a systematic review and network meta-analysis. JAMA Dermatol. 2020;156:659\u201367. https:\/\/doi.org\/10.1001\/jamadermatol.2020.0796.","journal-title":"JAMA Dermatol"}],"container-title":["American Journal of Clinical Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-025-00962-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40257-025-00962-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-025-00962-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T15:45:32Z","timestamp":1763048732000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40257-025-00962-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,19]]},"references-count":28,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["962"],"URL":"https:\/\/doi.org\/10.1007\/s40257-025-00962-8","relation":{},"ISSN":["1175-0561","1179-1888"],"issn-type":[{"value":"1175-0561","type":"print"},{"value":"1179-1888","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,19]]},"assertion":[{"value":"17 June 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 September 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This research was sponsored by Sanofi and Regeneron Pharmaceuticals Inc., ClinicalTrials.gov Identifier: NCT03687359. The study sponsors participated in the study design; collection, analysis, and interpretation of the data; writing of the report; and the decision to submit the article for publication.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Amy S. Paller is an investigator for AbbVie, Applied Pharma Research, Dermavant, Eli Lilly, Incyte, Janssen, Krystal Biotech, Regeneron Pharmaceuticals Inc., and UCB; a consultant for Aegerion Pharmaceuticals, Azitra, BioCryst, Boehringer Ingelheim, BMS, Eli Lilly, Janssen, Johnson & Johnson, Krystal Biotech, LEO Pharma, Novartis, Primus Pharmaceuticals, Regeneron Pharmaceuticals Inc., Sanofi, Seanergy, TWi Biotechnology, and UCB; and participates on data safety monitoring boards for AbbVie, Abeona Therapeutics, Catawba Research, Galderma, and InMed Pharmaceuticals. Amy S. Paller is an Editorial Board member of the American Journal of Clinical Dermatology. Amy Paller was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions. Danielle Marcoux is an advisory board member for Arcutis Biotherapeutics, Johnson & Johnson, Pierre Fabre, and Sanofi; is a consultant for AbbVie, Novartis, and Sanofi; an investigator for AbbVie, Amgen, Celgene, Eli Lilly, Incyte, LEO Pharma, Pfizer, Regeneron Pharmaceuticals Inc., Sanofi, and UCB; and a speaker for LEO Pharma, Pfizer, and Sanofi. Michele Ramien is a consultant for AbbVie, Eli Lilly, LEO Pharma, Pfizer, and Sanofi; and participates in a registry study for Sanofi. Eulalia Baselga is a speaker for Almirall; an investigator for AbbVie, Eli Lilly, and Pfizer; an investigator and consultant for Pierre Fabre Dermatologie; a consultant for Regeneron Pharmaceuticals Inc. and Sanofi; and a co-founder and consultant for Venthera. Vania Oliveira de Carvalho is a speaker for Expanscience, Galderma, Johnson & Johnson Consumer Health, Mantecorp Skincare, Megalabs, and Royal Canin; and an investigator for Sanofi. Ledit R.F. Ardusso is a consultant and\/or advisory board member, and\/or speaker for AstraZeneca, GSK, Novartis, and Sanofi. Marlies De Graaf is an investigator for AbbVie, Eli Lilly, LEO Pharma,\u00a0Pfizer, Regeneron Pharmaceuticals Inc., and Sanofi; a consultant for AbbVie, Almirall, Eli Lilly, LEO Pharma, Regeneron Pharmaceuticals Inc., and Sanofi; and a speaker for AbbVie, Eli Lilly, LEO Pharma, Novartis, Pfizer, Regeneron Pharmaceuticals Inc., and Sanofi. Suzanne Pasmans is an advisor, consultant, speaker, and\/or investigator for Boehringer Ingelheim, LEO Pharma, Novartis, Pierre Fabre, Regeneron Pharmaceuticals Inc., and Sanofi; and has received grants from BAP Medical, Boehringer Ingelheim, D&M, DeclaCare (part of BENU Netherlands), Micreos, Ministry of Health Welfare and Sport, Novartis, Pierre Fabre, and Zon MW. Mirna Toledo-Bahena is a speaker for AbbVie, Expanscience, Janssen, LEO Pharma, and Pierre Fabre; and an investigator for Pfizer and Sanofi. Cory Rubin is a speaker for AbbVie, Amgen, Bayer, BMS, Castle Creek Biosciences, Celgene, Cutanea, Dermavant, DermTech, Galderma, Genentech, Helsinn, Incyte, LEO Pharma, Novartis, Ortho Dermatologics, Pfizer, Promius Pharma, Regeneron Pharmaceuticals Inc., Sanofi, Sun Pharma, and UCB; a consultant for AbbVie, Allergan, Amgen, Biofrontera, Castle Creek Biosciences, Celgene, Dermavant, DermTech, Incyte, LEO Pharma, Novartis, Ortho Dermatologics, Pfizer, Promius Pharma, Regeneron Pharmaceuticals Inc., Sanofi, and UCB; and an investigator for BMS, Cara Therapeutics, Castle Creek Biosciences, DermTech, Janssen, LEO Pharma, and Sanofi. Joel C. Joyce has received consultant fees from Pfizer and Sanofi; speaker fees from Sanofi; and is a study investigator for AbbVie, Aclaris Therapeutics, Amgen, AstraZeneca, Bayer, BMS, Eli Lilly, Galderma, Incyte, Janssen, NFlection Therapeutics, Novartis, Pfizer, Sanofi, and UCB. Lara Wine Lee is an advisory board member for Castle Creek Biosciences, Eli Lilly, Pfizer, and Regeneron Pharmaceuticals Inc; is a consultant for AbbVie, Amryt Pharma, Kimberly-Clark, Krystal Biotech, Novartis, and Pyramid Biosciences; an investigator with AbbVie, Amgen, Amryt Pharma, Arcutis Biotherapeutics, Castle Creek Biosciences, Celgene, Eli Lilly, Galderma, Incyte, Mayne Pharma, Novartis, Pfizer, Regeneron Pharmaceuticals Inc., Sanofi, Target Pharma, Trevi Therapeutics, and UCB; and a speaker for Amryt Pharma and Krystal Biotech. Rajan Gupta has served as a consultant for Sanofi. Bryan Adams and Annie Zhang are employees of Sanofi and may hold stock and\/or stock options in the company. Marius Ardeleanu is an employee and shareholder of Regeneron Pharmaceuticals Inc.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"Qualified researchers may request access to study documents (including the clinical study report, study protocol with any amendments, blank case report form, and statistical analysis plan) that support the methods and findings reported in this manuscript. Individual anonymized participant data will be considered for sharing once the product and indication have been approved by major health authorities (e.g., FDA, EMA, PMDA), if there is legal authority to share the data, and there is not a reasonable likelihood of participant re-identification. Submit requests to\n                      \n                      .","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data Availability"}},{"value":"This study was conducted in accordance with the ethical standards of the responsible committees and with the Declaration of Helsinki and the International Council for Harmonisation guidelines for Good Clinical Practice. The trial was overseen by an independent data and safety monitoring board. The protocol was reviewed and approved by institutional review boards\/ethics committees at all centers.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Amy S. Paller and Annie Zhang contributed to the study concept and design. Ledit R.F. Ardusso, Vania Oliveira Carvalho, Danielle Marcoux, Michelle Ramien, Mirna Toledo-Bahena, Suzanne Pasmans, Marlies de Graaf, Joel C. Joyce, Cory Rubin, and Lara Wine Lee contributed to data acquisition. Rajan Gupta and Bryan Adams conducted the statistical analyses of the data. All authors interpreted the data, provided critical feedback on the manuscript, approved the final manuscript for submission, and are accountable for the accuracy and integrity of the manuscript.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 Contributions"}},{"value":"Written informed consent was obtained from all patients or their proxies.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed Consent"}},{"value":"Written informed consent was obtained from all patients or their proxies.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Not applicable.","order":10,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}}]}}